PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Injection of optimism as HIV vaccine trial begins

The first doses of an experimental HIV vaccine have been delivered in the phase 1 clinical trial. International AIDS Vaccine Initiative (IAVI), a non-profit scientific research organisation – alongside biotechnology company Moderna and the Bill & Melinda Gates Foundation – aims to build on the results seen in a proof-of-concept trial for the associated antigens.

“We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the setting of HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world,” said Stephen Hoge, president of Moderna.

“We believe advancing this HIV vaccine programme in partnership with IAVI and Scripps Research is an important step in our mission to deliver on the potential for mRNA to improve human health,” he added.

The phase 1 IAVI G002 trial is taking place at George Washington University School of Medicine and Health Sciences, in Washington, DC. It is designed to test the idea that priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific types of B-cell responses and guide their early growth toward broadly neutralising antibody (bnAb) development.

An immunogen is a substance inducing an immune response and BnAbs are neutralising antibodies that neutralise several viral strains of HIV-1. The induction of BnAbs is widely considered to be a goal of HIV vaccination and this is the first step in the process.

The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026